

# BRIXADI<sup>®</sup> DOSING CONVERSION TABLES

## Sublingual Buprenorphine and Suggested Corresponding Brixadi<sup>®</sup> Dose

Daily Dose of Sublingual Buprenorphine	Brixadi <sup>®</sup> Dosage <sup>1</sup>	
	Brixadi <sup>®</sup> Weekly <i>Administered in 7-day intervals (+/- 2 days)</i>	Brixadi <sup>®</sup> Monthly <i>Administered in 28-day intervals (+/- 1 week)</i>
≤ 6 mg	8 mg	—
8-10 mg	16 mg	64 mg
12-16 mg	24 mg	96 mg
18-24 mg	32 mg	128 mg

## Sublocade<sup>®</sup> and Suggested Corresponding Brixadi<sup>®</sup> Dose

Sublocade <sup>®</sup> Monthly Dose <sup>2</sup>	Brixadi <sup>®</sup> Dosage	
	Brixadi <sup>®</sup> Weekly <i>Administered in 7-day intervals (+/- 2 days)</i>	Brixadi <sup>®</sup> Monthly <i>Administered in 28-day intervals (+/- 1 week)</i>
100 mg	24 mg	96 mg
300 mg	32 mg	128 mg

1. Brixadi<sup>®</sup> weekly and Brixadi<sup>®</sup> monthly are different formulations. Weekly injections cannot be combined to yield a monthly dose. Patients may be transitioned from Brixadi<sup>®</sup> weekly to Brixadi<sup>®</sup> monthly OR monthly to weekly based on clinical judgment and patient preference.
2. There have been no clinical studies looking at transitioning to and from Sublocade<sup>®</sup> and Brixadi<sup>®</sup>. The suggested dose equivalents are based on steady state plasma concentrations.

### References

- FDA. (2023). *Brixadi Prescribing Information*.  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/210136Orig1s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210136Orig1s000lbl.pdf)
- Lintzeris, N., Dunlop, A., & Schulz, M. (2024). *Long-acting injectable buprenorphine (LAIB) for opioid dependence treatment: Guidance document (2nd ed.)*. NSW Ministry of Health.  
<https://www.health.nsw.gov.au/aod/Publications/laib.pdf>